Forest Laboratories submits NDA to FDA for combination drug to treat Alzheimer's disease
US-based Forest Laboratories has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for a fixed-dose combination (FDC) of memantine HCl extended release (ER) and donepezil HCl to treat moderate to severe Alzheimer's t…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Alzheimer's | Donepezil | Food and Drug Administration (FDA) | Namenda | New Drug Applications | Pharmaceuticals